Faruqi & Faruqi, LLP Investigates Claims for Altimmune Investors: Action Reminder
Faruqi & Faruqi, LLP, a prominent national securities law firm, is currently investigating potential claims on behalf of investors in Altimmune, Inc. This inquiry arises amidst significant developments related to the company's Phase 2b trial results and the subsequent impact on their stock value. Investors who suffered losses of over $75,000 in Altimmune between August 10, 2023, and June 25, 2025, are notably urged to take action.
The investigation focuses on Altimmune's announcement made on June 26, 2025, regarding topline results from the IMPACT Phase 2b MASH trial involving Pemvidutide for treating NASH (Non-alcoholic steatohepatitis). Investors were reportedly given inflated expectations leading up to these results. However, the findings revealed that the company failed to achieve statistical significance in the primary endpoint related to fibrosis reduction.
While there was a positive trend in the results, the magnitude of placebo response resulted in the inability to meet statistical significance. This prompted the defendants to express indifference and attribute the outcome to the trial's Phase 2 status. They suggested enhanced results could be anticipated in the upcoming Phase 3 trial, but this did little to reassure investors.
The market's response to the news was swift and severe, with Altimmune’s stock price plummeting by 53.2%, falling from $7.71 per share on June 25, 2025, to $3.61 per share the following day. This drastic decline raised concerns among investors, prompting the firm to remind them of the October 6, 2025, deadline to apply for lead plaintiff status in the ongoing federal securities class action against the company.
The role of a lead plaintiff is significant as it involves guiding the litigation on behalf of the class of investors, typically including those who have suffered the most financially. However, the firm assures that those who choose not to take this role can still participate in any recovery they might be entitled to.
In light of these events, Faruqi & Faruqi, LLP encourages any individual with information regarding Altimmune's practices to come forward. This includes former employees, shareholders, and whistleblowers, as their insight may be crucial to building a strong case. The legal pathways for affected investors vary, and discussing one's options with experienced securities attorneys could be beneficial in navigating these complexities.
For those interested in pursuing any claims or seeking more information about the class action, they can reach out directly to Joshua Wilson, a partner at Faruqi & Faruqi, at 877-247-4292 or 212-983-9330 (Ext. 1310). Additionally, further resources and details about the ongoing investigations can be found on the firm’s official website. It’s a critical time for investors to act and safeguard their legal rights concerning their investments in Altimmune, Inc. The significant drop in stock value represents a potential avenue for recovery for those who lost substantial sums during this period. Firm representation can provide the necessary advocacy for affected investors in the challenging landscape of federal securities litigation.
In conclusion, the situation surrounding Altimmune is reflective of broader trends in securities law where timely action can be critical. Investors must stay informed and proactive in order to protect their financial interests. As the investigation unfolds, updates will be made available through various channels including LinkedIn, X, and Facebook, ensuring stakeholders remain informed throughout the legal process.
The investigation focuses on Altimmune's announcement made on June 26, 2025, regarding topline results from the IMPACT Phase 2b MASH trial involving Pemvidutide for treating NASH (Non-alcoholic steatohepatitis). Investors were reportedly given inflated expectations leading up to these results. However, the findings revealed that the company failed to achieve statistical significance in the primary endpoint related to fibrosis reduction.
While there was a positive trend in the results, the magnitude of placebo response resulted in the inability to meet statistical significance. This prompted the defendants to express indifference and attribute the outcome to the trial's Phase 2 status. They suggested enhanced results could be anticipated in the upcoming Phase 3 trial, but this did little to reassure investors.
The market's response to the news was swift and severe, with Altimmune’s stock price plummeting by 53.2%, falling from $7.71 per share on June 25, 2025, to $3.61 per share the following day. This drastic decline raised concerns among investors, prompting the firm to remind them of the October 6, 2025, deadline to apply for lead plaintiff status in the ongoing federal securities class action against the company.
The role of a lead plaintiff is significant as it involves guiding the litigation on behalf of the class of investors, typically including those who have suffered the most financially. However, the firm assures that those who choose not to take this role can still participate in any recovery they might be entitled to.
In light of these events, Faruqi & Faruqi, LLP encourages any individual with information regarding Altimmune's practices to come forward. This includes former employees, shareholders, and whistleblowers, as their insight may be crucial to building a strong case. The legal pathways for affected investors vary, and discussing one's options with experienced securities attorneys could be beneficial in navigating these complexities.
For those interested in pursuing any claims or seeking more information about the class action, they can reach out directly to Joshua Wilson, a partner at Faruqi & Faruqi, at 877-247-4292 or 212-983-9330 (Ext. 1310). Additionally, further resources and details about the ongoing investigations can be found on the firm’s official website. It’s a critical time for investors to act and safeguard their legal rights concerning their investments in Altimmune, Inc. The significant drop in stock value represents a potential avenue for recovery for those who lost substantial sums during this period. Firm representation can provide the necessary advocacy for affected investors in the challenging landscape of federal securities litigation.
In conclusion, the situation surrounding Altimmune is reflective of broader trends in securities law where timely action can be critical. Investors must stay informed and proactive in order to protect their financial interests. As the investigation unfolds, updates will be made available through various channels including LinkedIn, X, and Facebook, ensuring stakeholders remain informed throughout the legal process.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.